(12) United States Patent (10) Patent No.: US 8,841,436 B2 Gorodeski Et Al
Total Page:16
File Type:pdf, Size:1020Kb
USOO8841436B2 (12) United States Patent (10) Patent No.: US 8,841,436 B2 Gorodeski et al. (45) Date of Patent: Sep. 23, 2014 (54) SCREENING, DIAGNOSING, TREATING AND 5,139,941 A 8/1992 Muzyczka et al. ............ 435/456 PROGNOSIS OF PATHOPHYSIOLOGIC 5,252.479 A 10/1993 Srivastava .......... 435/235.1 5,427,916 A 6/1995 Gewirtz et al. ................... 435/5 STATUS BY RNA REGULATION 5,849,902 A 12/1998 Arrow et al. ... 536,245 2002fO086356 A1 7, 2002 TuSchlet al. ... ... 435/69.1 (75) Inventors: George Gorodeski, Beachwood, OH 2002/0173478 A1 11/2002 Gewirtz. ......... 514.f44 A (US); Judith Potashkin, Gurnee, IL 2004/0014113 A1 1/2004 Yang et al. ..... ... 435/6.11 (US); Bentley Cheatham, Durham, NC 2004/001817.6 A1 1/2004 Tolentino et al. .. 424.93.21 (US s s 2005/0022725 A1 2/2005 Jurgensen et al. ............ 117/104 2005. O153918 A1 7, 2005 Chabot et al. ...... 514.f44 A 2006/0105360 A1 5/2006 Croceet al. .... ... 435.6.18 (73) Assignees: University Hospitals Cleveland 2006/0292616 A1 12/2006 Neely et al. .................. 435/6.12 Medical Center, Cleveland, OH (US); 2007/00264.03 A1 2/2007 Hatzigeorgiou et al. ... 435/6.11 Rosalind Franklin University of 2008/0171715 A1 7/2008 Brown et al. ................... 514,44 Medicine and Science, an Illinois Corporation, North Chicago, IL (US) FOREIGN PATENT DOCUMENTS WO WO93/24641 12/1993 (*) Notice: Subject to any disclaimer, the term of this WO WO94f13788 6, 1994 patent is extended or adjusted under 35 WO WO 2005078139 A2 8, 2005 U.S.C. 154(b) by 54 days. WO WO 2005.1.18806 A2 12/2005 WO WO 2005.1.18806 A2 2, 2006 (21) Appl. No.: 12/450,124 WO WO 2005.1.18806 A 6, 2006 WO WO 2005.1.18806 B T 2006 (22) PCT Filed: Mar. 13, 2008 OTHER PUBLICATIONS (86). PCT No.: PCT/US2O08/OO3298 Kong et al. P2X7 nucleotide receptors mediate caspase-8/9/3-depen S371 (c)(1), dent apoptosis in rat primary cortical neurons. Purinergic Signaling (2), (4) Date: Apr. 14, 2010 2005, 1:337-347.* Lagos-Quintana et al. New microRNAS from mouse and human. (87) PCT Pub. No.: WO2008/115387 RNA 2003, 9; 175-179.* PCT Pub. Date: Sep. 25, 2008 Ambros, “miRNAS: tiny regulators with great potential” Cell, 107.823-826 (2001). (65) Prior Publication Data Ambros, “The functions of animal microRNAs.” Nature, 431:350 US 2010/O19688.6 A1 Aug. 5, 2010 355 (2004). Anderson, “Human gene therapy.” Nature, Supplement, 392:25-30 (1998). Related U.S. Application Data Bartel, et al., “MicroRNAs. At the Root of Plant Development?” (60) Provisional application No. 60/918,242, filed on Mar. Plant Physiol., 132:709-717 (2003). 15, 2007. (Continued) (51) Int. Cl. C7H 2L/04 (2006.01) Primary Examiner — Kimberly Chong CI2N IS/II3 (2010.01) CI2O I/68 (2006.01) (74) Attorney, Agent, or Firm — Medlen & Carroll, LLP (52) U.S. Cl. CPC ........ CI2N 15/1138 (2013.01); C12N 2320/11 (57) ABSTRACT (2013.01); C12O 2600/106 (2013.01): CI2O I/6809 (2013.01); C12N 23 10/14 (2013.01); A relationship between cancer and ribonucleic acid (RNA) CI2O 2600/178 (2013.01); C12N 2330/10 regulation is described by determining intracellular levels of (2013.01); C12O 2600/1 18 (2013.01): CI2O niRNA regulators. Generally, mRNA levels are decreased in I/6886 (2013.01) cancer cells that may be a reflection of either reduced mRNA USPC .......... 536/24.5:536/24.31:536/24.1; 435/6; expression and/or increased mRNA degradation. miRNAs 435/325; 435/375 are identified that hybridize to an mRNA that are suspected to (58) Field of Classification Search mediate intracellular mRNA steady state levels. Alterna None tively, ribonucleic acid binding protein (RBP) levels may also See application file for complete search history. mediate intracellular mRNA steady state levels. In particular, (56) References Cited this invention demonstrates an effective clinical management strategy for uterine cell cancers may be implemented by U.S. PATENT DOCUMENTS taking advantage of an exemplary relationship between P2X, mRNA and miRNAs including, but not limited to, miR-186 4,235,871 A 11/1980 Papahadjopoulos et al. 424/450 and/or miR-150. 4,501,728 A 2, 1985 Geho et al. .................... 424/450 4,837,028 A 6, 1989 Allen ........................... 424f1.21 4,987,071 A 1/1991 Cech et al. ... ... 435,91.31 5,019,369 A 5/1991 Presant et al. ............... 424f1.21 9 Claims, 18 Drawing Sheets US 8,841436 B2 Page 2 (56) References Cited Gerlach, et al., “Multidrug resistance.” Cancer Surveys, 5:25-46 (1986). OTHER PUBLICATIONS Goldie and Coldman, “The Genetic Origin of Drug Resistance in Neoplasms: Implications for Systemic Therapy.” Cancer Research, Bartel, et al., “MicroRNAS: genomics, biogenesis, mechanism, and 44:3643-3653 (1984). function.” Cell, 116:281-297 (2004). Gorodeski, et al., “Retinoids, sex steroids, and glucocorticoids regu Brummelkamp, et al., “A System for Stable Expression of Short late ectocervical cell envelope formation but not the level of the Interfering RNAs in Mammalian Cells.” Science, 296:550-553 envelope precursor, involucrin.” Differentiation, 42:75-80 (1989). (2002). Gorodeski, et al., “Characterization of paracellular permeability in Brummelkamp, et al., “A System for Stable Expression of Short cultured human cervical epithelium: regulation by extracellular Interfering RNAs in Mammalian Cells.” Supplemental Data. Sci ATPJ Soc Gynecol Investig., 1:225-233 (1994a). ence, 296:550-553 (2002). Gorodeski, et al., “Human uterine cervical epithelial cells grown on Brummelkamp, et al., “A System for Stable Expression of Short permeable support-a new model for the study of differentiation and Interfering RNAS in Mammalian Cells.” Supplemental Data Figure. transepithelial transport.” Differentiation, 56: 107-118 (1994b). Science, 296:550-553 (2002). Guhaniyogi, et al., “Regulation of mRNA stability in mammalian Buell, et al., “Gene structure and chromosomal localization of the cells.” Gene, 265:11-23 (2001). human P2X7 receptor.” Receptors Channels 5:347-354 (1998). Hammann, et al., "Length variation of helix III in a hammerhead Burd, et al., “Conserved structures and diversity of functions of ribozyme and its influence on cleavage activity.” Antisense and RNA-binding proteins.” Science, 265:615-621 (1994). Nucleic Acid Drug Dev, 9:25-31 (1999). Calin, et al., “Frequent deletions and down-regulation of miRNA Hentze, “Translational regulation: versatile mechanisms for meta genes miR-15 and miR-16 at 13q14 in chronic lymphocytic leuke bolic and developmental control.” Curr: Op. Biol. 7:393-398 (1995). mia.” Proc. Natl Acad. Sci. USA, 99:15524-15529 (2002). Higgins, et al., “CLUSTAL: a package for performing multiple Chen, et al., “MicroRNAS Modulate Hematopoietic Lineage Differ sequence alignment on a microcomputer.” Gene, 73:237-244 (1988). entiation.” Science, 303:83-86 (2004). Huang, et al., “Dynamic programming algorithms for restriction map Chen, et al., “MicroRNAS Modulate Hematopoietic Lineage Differ comparison.” Computer Applications in the Biosciences, 8:1-6 entiation.” Science, 303:83-86 Supplemental Online Material (1992). Revised (2004). Hutvagner, et al., “A microRNA in a multiple-turnover RNAi enzyme Cheng, et al., “Antisense inhibition of human mRNAs and indications complex” Science, 297:2056-2060 (2002). for an involvement of miRNA in cell growth and apoptosis.” Nucleic James, "Nucleic acid and polypeptide aptamers: a powerful approach Acids Research, 33:1290-1297 (2005). Colas, et al., “Genetic selection of peptide aptamers that recognize to ligand discovery.” Current Opinion in Pharmacology, 1:540-546 and inhibit cyclin-dependent kinase 2.” Nature, 380:548-550 (1996). (2001). Corpet, "Multiple sequence alignment with hierarchical clustering.” Kidner, et al., “Macro effects of microRNAs in plants.” Trends Nucleic Acids Research, 16:10881-90 (1988). Genet., 19:13-16 (2003). Couzin, “Breakthrough of the Year. Small RNAS Make Big Splash.” Kohler, et al., “Continuous cultures of fused cells secreting antibody Science, 298:2296-2297 (2002). of predefined specificity.” Nature, 256:495-497 (1975). Croce, et al., “miRNAs, cancer, and stem cell division.” Cell, 122:6-7 Kozbor, et al., “The Production of Monoclonal Antibodies From (2005). Human Lymphocytes.” Immunology Today, 4:72 (1983). Dennis, "Small RNAS: The genome's guiding hand?' Nature, Lee, et al., “The C. elegans heterochronic gene lin-4 encodes Small 420:732 (2002). RNAs with antisense complementarity to lin-14.” Cell, 75:843-854 Doench, et al., “siRNAs can function as miRNAs.” Genes Dev., (1993). 17:438-442 (2003). Lee, et al., “Expression of Small interfering RNAS targeted against Doench, et al., “Specificity of microRNA target selection in transla HIV-1 rev transcripts in human cells.” Nat. Biotechnol. 20:500-505 tional repression.” Genes, Dev. 18:504-511 (2004). (2002). Dornburg, “Reticuloendotheliosis viruses and derived vectors.” Gene Lewis, et al., “Prediction of mammalian miRNA targets.” Cell, Therap., 2:301-310 (1995). 115:787-798 (2003). Eglitis, et al., “Retroviral Vectors for Introduction of Genes into Lewis, et al., "Conserved seed pairing, often flanked by adenosines, Mammalian Cells.” Biotechniques, 6(7):608-614 (1988). indicates that thousands of human genes are microRNA targets.” Elbashir, et al., “RNA interference is mediated by 21- and Cell, 120:15-20 (2005). 22-nucleotide RNAs.” Genes Dev., 15:188-200 (2001). Li, et al., “The P2X, Receptor. A novel biomarker of uterine Fienberg, et al., "A technique for radiolabeling DNA restriction epithelial cancers.” Cancer Epidemiology Biomarkers and Preven endonuclease fragments to high specific activity.” Anal. Biochem.. tion, 15: 1-8 (2006a). 132:6-13 (1983). Li, et al., “The P2X, receptor. A novel biomarker of uterine epithelial Fienberg, et al., “A technique for radiolabeling DNA restriction cancers.” Cancer Epidemiology Biomarkers and Prevention, endonuclease fragments to high specific activity.” Addendum. Anal. 15:1906-1913 (2006b). Biochem., 137(1):266-7 (1983). Llave, et al., “Cleavage of Scarecrow-like mRNA targets directed by Feng, et al., “ATP ligation stimulates GRK-3-mediated phosphoryla a class of Arabidopsis miRNA.” Science, 297:2053-2056 (2002).